Data gathered: July 10
AI Stock Analysis - NovoCure (NVCR)
Analysis generated July 15, 2024. Powered by Chat GPT.
NovoCure Ltd. (NASDAQ: NVCR) is a global oncology company that develops and commercializes innovative therapeutic products for treating patients with cancer. The cornerstone of the company's technology is based on Tumor Treating Fields (TTFields), a unique therapeutic approach that utilizes electric fields to disrupt cancer cell division. Founded in 2000, NovoCure has been at the forefront of developing TTFields to offer non-invasive cancer treatment options. The company's flagship product, Optune, has shown efficacy in treating glioblastoma multiforme (GBM), particularly for patients with recurrent or newly diagnosed conditions.
Stock Alerts - NovoCure (NVCR)
 |
NovoCure | July 1 Employee Rating is up by 3.1% over the last month. |
|
NovoCure | June 10 Price is up by 7.2% in the last 24h. |
|
NovoCure | June 5 Insider Alert: Stafford Kristin is selling shares |
|
NovoCure | June 3 Employee Rating is down by 2.9% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for NovoCure
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 74 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 44,000 | Sign up | Sign up | Sign up |
| Employee Rating | 66 | Sign up | Sign up | Sign up |
| Google Trends | 5 | Sign up | Sign up | Sign up |
| Patents | 195 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,387 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,722 | Sign up | Sign up | Sign up |
| Twitter Mentions | 23 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 48 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,429 | Sign up | Sign up | Sign up |
About NovoCure
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.
| Price | $18.19 |
| Target Price | Sign up |
| Volume | 926,410 |
| Market Cap | $1.95B |
| Year Range | $15.37 - $33.41 |
| Dividend Yield | 0% |
| Analyst Rating | 83% buy |
| Earnings Date | July 24 '25 |
| Industry | Medical & Dental Instruments |
In the news
 |
Strong week for NovoCure (NASDAQ:NVCR) shareholders doesn't alleviate pain of three-year lossJune 30 - Yahoo |
|
NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?June 29 - Yahoo |
 |
NovoCure’s (NVCR) “Overweight” Rating Reaffirmed at Piper SandlerJune 28 - ETF Daily News |
|
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Rating of “Moderate Buy” from BrokeragesJune 28 - ETF Daily News |
|
Exchange Traded Concepts LLC Has $674,000 Holdings in NovoCure Limited (NASDAQ:NVCR)June 21 - ETF Daily News |
|
What Makes NovoCure (NVCR) a New Buy StockJune 18 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 155M | 39M | 116M | -34M | -35M | -0.310 |
| Q4 '24 | 161M | 33M | 128M | -66M | -11M | -0.610 |
| Q3 '24 | 155M | 35M | 120M | -31M | -30M | -0.280 |
| Q2 '24 | 150M | 35M | 116M | -33M | -31M | -0.310 |
| Q1 '24 | 139M | 34M | 105M | -39M | -37M | -0.360 |
Insider Transactions View All
| Hung David filed to sell 12,195 shares at $17.3. June 4 '25 |
| VERNON W ANTHONY filed to sell 167,887 shares at $17.3. June 4 '25 |
| Ocean Allyson J filed to sell 3,054 shares at $17.3. June 4 '25 |
| HILLEMAN JERYL L filed to sell 5,591 shares at $17.3. June 4 '25 |
| Scannell Timothy J filed to sell 6,018 shares at $17.3. June 4 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Align TechnologyALGN |
$200.48 0% | 41 |
 |
DentsplyXRAY |
$16.57 0% | 46 |
 |
LeMaitre VascularLMAT |
$84.55 0% | 37 |
 |
iRhythm TechnologiesIRTC |
$132.88 0% | 44 |
 |
DanaherDHR |
$200.96 0% | 36 |
Read more about NovoCure (NVCR) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of NovoCure?
The Market Cap of NovoCure is $1.95B.
When does NovoCure report earnings?
NovoCure will report its next earnings on July 24 '25.
What is the current stock price of NovoCure?
Currently, the price of one share of NovoCure stock is $18.19.
How can I analyze the NVCR stock price chart for investment decisions?
The NVCR stock price chart above provides a comprehensive visual representation of NovoCure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovoCure shares. Our platform offers an up-to-date NVCR stock price chart, along with technical data analysis and alternative data insights.
Does NVCR offer dividends to its shareholders?
As of our latest update, NovoCure (NVCR) does not offer dividends to its shareholders. Investors interested in NovoCure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of NovoCure?
Some of the similar stocks of NovoCure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and Danaher.
.